Autoimmune Dysautonomia Evaluation

Clinical Utility of Autoimmune Dysautonomia Evaluation

February 2011

Seropositivity can help distinguish autoimmune dysautonomia from chemotherapy side effects. Finally, a rise in antibody titer in a previously seropositive patient can suggest cancer recurrence.

< Previous Slide

Clinical Utility

Next Slide >

 

Jump to section:

• Introduction
• New Profile
• Autoimmune Dysautonomia
• Autoimmune Dysautonomia
• Autoimmune Dysautonomia^1,2
• Pandysautonomia
• Limited Dysautonomia³
• Objective Testing
• Thermoregulatory Sweat Testing
• Antibody Testing
• Ganglionic Acetylcholine Receptor (AChR) Autoantibody
• Ganglionic Acetylcholine Receptor (AChR) Autoantibody
• Autoimmune Dysautonomia Antibody Profile
• Autoimmune Dysautonomia Evaluation Testing Algorithm
• Clinical Utility of Autoimmune Dysautonomia Evaluation
• Clinical Utility of Autoimmune Dysautonomia Evaluation
• Summary
• References
• Questions?